高级检索
    评价者: 王先明, 文献合成者: 肖瑜. BOLERO-2研究解读: 依维莫司联合依西美坦在激素受体阳性进展性乳腺癌的临床实践依据[J]. 循证医学, 2016, 16(3): 145-148. DOI: 10.12019/j.issn.1671-5144.2016.03.007
    引用本文: 评价者: 王先明, 文献合成者: 肖瑜. BOLERO-2研究解读: 依维莫司联合依西美坦在激素受体阳性进展性乳腺癌的临床实践依据[J]. 循证医学, 2016, 16(3): 145-148. DOI: 10.12019/j.issn.1671-5144.2016.03.007
    shu
    Reviewer: WANG Xian-ming, Literature Co-worker: XIAO Yu. The Interpretation of BOLERO-2 Trial: Clinical Application Analysis on Everolimus Plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer[J]. Journal of Evidence-Based Medicine, 2016, 16(3): 145-148. DOI: 10.12019/j.issn.1671-5144.2016.03.007
    Citation: Reviewer: WANG Xian-ming, Literature Co-worker: XIAO Yu. The Interpretation of BOLERO-2 Trial: Clinical Application Analysis on Everolimus Plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer[J]. Journal of Evidence-Based Medicine, 2016, 16(3): 145-148. DOI: 10.12019/j.issn.1671-5144.2016.03.007
    shu

    BOLERO-2研究解读: 依维莫司联合依西美坦在激素受体阳性进展性乳腺癌的临床实践依据

    The Interpretation of BOLERO-2 Trial: Clinical Application Analysis on Everolimus Plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer

      摘要
      • HTML全文
      • 参考文献(5)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回